Get the Stockscreener App
38.97
1.17%
-0.46
Uniqure Nv stock is traded at $38.97, with a volume of 1.35M.
It is down -1.17% in the last 24 hours and down -20.23% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$39.43
Open:
$39.3
24h Volume:
1.35M
Relative Volume:
0.66
Market Cap:
$2.68B
Revenue:
$18.09M
Net Income/Loss:
$-208.87M
P/E Ratio:
-11.09
EPS:
-3.5125
Net Cash Flow:
$-178.15M
1W Performance:
-3.18%
1M Performance:
-20.23%
6M Performance:
+55.38%
1Y Performance:
+156.21%
1-Day Range:
$37.33
$39.44
1-Week Range:
$37.33
$41.92
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
38.97 | 2.68B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
uniQure (QURE) to Release Earnings on Wednesday - MarketBeat
uniQure N.V. Revenue Breakdown – BIVA:QURE/N - TradingView
Aberdeen Group plc Reduces Holdings in uniQure NV - GuruFocus
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
uniQure N.V. to announce Q2 2026 financial results on July 29 - scanx.trade
uniQure to Announce Second Quarter 2026 Financial Results - The Manila Times
uniQure sets July 29 webcast after Q2 financial results - Stock Titan
JPMorgan Chase & Co. Increases Stake in uniQure NV - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $46 - Moomoo
uniQure (QURE) Proxy filing Summary - Quartr
Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure - Stock Titan
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold? - MSN
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise - Yahoo Finance
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - The Globe and Mail
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway - Yahoo Finance
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - GuruFocus
UniQure (QURE) now trades above golden cross: Time to buy? - MSN
JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares - Stock Titan
uniQure's Huntington's prospects brighten after FDA shift - S&P Global
If You Invested $1,000 in Uniqure (QURE) - Stock Titan
The Technical Signals Behind (QURE) That Institutions Follow - Stock Traders Daily
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
UniQure soars as Cantor upgrades on plans to seek gene therapy nod - MSN
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
uniQure (QURE) Status Update Summary - Quartr
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CEO sells 21,082 shares after option exercise under 10b5-1 plan - Stock Titan
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to sales forward of uniQure N.V. – FWB:UQ1 - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action - The National Law Review
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CMO sells 30,000 shares and exercises 10,000 stock options - Stock Titan
uniQure (QURE) director sells 21,167 shares after exercising options - Stock Titan
UniQure (NASDAQ: QURE) affiliate plans 21,082-share option sale; June open-market sales listed - Stock Titan
Precision Trading with Uniqure N.v. (QURE) Risk Zones - Stock Traders Daily
Price to earnings forward of uniQure N.V. – NASDAQ:QURE - TradingView
Price to earnings forward of uniQure N.V. – LSE:0EE0 - TradingView
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Form 144 uniQure N.V. For: 30 June - Investing.com UK
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
Form 144 uniQure N.V. For: 30 June By Investing.com - Investing.com Nigeria
uniQure (QURE) CMO auto-sells shares for RSU tax withholding, keeps stake - Stock Titan
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):